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Muscle UCP-3 mRNA levels are elevated in weight loss associated
with gastrointestinal adenocarcinoma in humans
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The mitochondrial uncoupling proteins-2 and -3 are putative mediators of thermogenesis and energy expenditure. We
measured the mRNA levels of uncoupling proteins-2 and -3 in skeletal muscle from 12 gastrointestinal adenocarcinoma
patients, of whom six had stable weight and six had lost 2–18 kg, and from six healthy controls undergoing elective surgery.
Uncoupling proteins-3 mRNA levels were signiﬁcantly higher in the muscle of the cancer patients with weight loss (2.2+0.47
arbitrary units) compared both with controls (0.39+0.20) and with cancer patients who had not lost weight (0.47+0.23;
P50.02). Uncoupling proteins-2 mRNA levels did not differ signiﬁcantly between groups. Elevations in muscle uncoupling
proteins-3 activity may enhance energy expenditure and this in turn could contribute to tissue catabolism.
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Some degree of weight loss occurs in over 80% of cancer patients,
and is strongly associated with poor outcome and early death
(Puccio and Nathanson, 1997; De Wyes et al, 1980). The aetiology
of weight loss in malignancy is multifactorial and may include
increases in circulating cytokines, reductions in food intake, and
alterations in metabolism (Tisdale et al, 1996). Resting energy
expenditure is increased in some animal and human cancers, and
is thought to contribute to weight loss (Bosaeus et al, 2001). The
sites and mechanisms of excessive heat production in human
cancer cachexia are however unknown.
The uncoupling proteins (UCPs) are a family of mitochondrial
membrane proteins. UCP-1 is restricted to brown adipose tissue
(BAT) where it uncouples oxidative phosphorylation and generates
heat instead of ATP (Klaus et al, 1991). Other UCPs include UCP-
2 (found in many tissues) and UCP-3 (expressed in BAT and skeletal
muscle) (Boss et al, 1997; Fleury et al, 1997). Both have uncoupling
activity in vitro and may mediate the increased energy expenditure
implicated in energy balance. Transgenic mice over-expressing
UCP-3 in muscle are lean despite exhibiting hyperphagia; oxygen
consumption in the transgenic animals was increased by 91% indicat-
ing an increase in metabolic rate (Clapham et al, 2000). The exact
roles of the various UCP isoforms in vivo are still debated and are
reviewed elsewhere (Ricquier and Bouillaud, 2000).
We recently found increased UCP-2 and -3 mRNA levels in the
muscle of mice with severe cachexia due to the MAC-16 (Bing et
al, 2000) This non-metastasizing adenocarcinoma is histologically
similar to human gastrointestinal tumours and causes profound
weight loss despite only modest reductions in food intake. Here,
we aimed to determine whether UCP-2 and -3 expression was
similarly up-regulated in human cancer.
METHODS
Patient characteristics
We studied 12 patients with histologically diagnosed adenocarci-
noma of the GI tract undergoing elective laparotomy. Subjects were
excluded from the study if there was evidence of intercurrent infec-
tion at the time of surgery, or mechanical obstruction of the gut.
Six had weight loss of 2–18 kg over a period of 4–12 weeks prior
to surgery, as documented in medical notes, while the remainder
had stable weight documented on at least two occasions over a
similar period. Weights were measured on a single set of scales
in the surgical outpatient clinic. All patients were operated during
a weekly list to minimize the differences in fasting times prior to
sample collection. Controls were undergoing laparotomy for a
benign disease (Table 1) and had a documented stable weight for
at least 8 weeks prior to surgery.
Fully informed and written consent was obtained in all cases and
the study protocol was approved by the Sefton Ethics Committee.
Tissue collection and processing
At laparotomy, samples of rectus abdominus muscle (approxi-
mately 10 mg) were collected and immediately placed in storage
solution (RNAlater
1 Ambion Inc., Austin, TX, USA) to stabilize
RNA pending transport to the laboratory and storage at 7208C.
After collection, all samples were processed at the same time using
a commercial spin column kit to isolate total mRNA (Neucleo-
spin
1 Clontech Labs Inc., CA, USA). The amount and purity of
isolated RNA was calculated using spectrometry at 260/280 nM.
Measurement of UCP-2 and -3 mRNA
Semi-quantitative RT–PCR was performed to calculate amounts of
UCP-2 and -3 mRNA, relative to the housekeeping gene, hypox-
anthine phosphoribosyl transferase (HPRT). One ng of total
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speciﬁc primers (0.2 mM each of forward and reverse), reverse tran-
scriptase, DNA polymerase, MgCl2 (1.5 mM) (OneStep
1 Abgene,
Epsom, Surrey, UK). A further 1 ng sample was added to an iden-
tical PCR mixture containing HPRT-speciﬁc primers. Preliminary
experiments identiﬁed RNA template concentrations, which yielded
a product within a linear range for both HPRT and the UCPs,
under the standard conditions deﬁned below, and PCR products
were sequenced to ensure speciﬁcity.
cDNA synthesis and PCR were completed in a single reaction:
30 min at 478C for ﬁrst-strand generation, inactivation for 2 min
at 958C, followed by 30 cycles (20 s at 948C, 30 s at 568C, 1 min
at 728C) and a ﬁnal extension step at 728C for 5 min. After comple-
tion, a 5 ml aliquot of the HPRT reaction was mixed with 10 mlo f
the UCP-2 or -3 reaction and the resulting mixture subjected to
electrophoresis on a 1% agarose gel, stained with ethidium
bromide. Bands were visualized and quantitated using a digital
image analysis system (Kodak 1-D Eastman Kodak Co, MA,
USA). Optical density was calculated for the two products and
the results expressed as a ratio of UCP-2 product to HPRT product.
A negative control (without reverse transcriptase) was run with
each experiment to ensure the absence of DNA contamination.
RESULTS
There were no signiﬁcant differences in age between the three groups
(Table 1). Most of the cancer group were male, while three of the
control group were female. The origins of the adenocarcinomas were
similarly distributed in the cancer patients with or without weight
loss. In the cancer with documented weight loss group, this ranged
from 2–18 kg. BMI and serum albumin were signiﬁcantly lower in
the cancer patients with weight loss than in both other groups.
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Table 1 Patient data for the three studied groups; including diagnosis and BMI at the time of surgery, and documented weight change
Mean age Mean BMI Weight change at Mean serum
Adenocarcinoma patients Sex (years) Diagnosis (kg m
72) sampling (kg) albumin (g l
71)
Group 1 (with weight loss) M Adenocarcinoma stomach 718.0
M Adenocarcinoma stomach 75.0
M6 3 +4.8 Adenocarcinoma oesophagus 25+0.8 717.0 35.8+1.45
M Adenocarcinoma stomach 72.5
M Adenocarcinoma colon 711.5
M Adenocarcinoma stomach 715.5
Group 2 (without weight loss) M Adenocarcinoma oesophagus 0
M Adenocarcinoma oesophagus 0
M Adenocarcinoma stomach +0.5
M7 0 +2.3 Adenocarcinoma stomach 27+0.7 0 38.8+0.48
M Adenocarcinoma colon 70.5
F Adenocarcinoma stomach 0
Controls (no malignancy no weight loss) M Hernia repair 0
F Cholecystectomy 0
F Cholecystectomy 0
F6 2 +4.6 Hernia repair 27+0.7 0 39.5+0.20
F Leiomyoma stomach 0
M Reversal of colostomy +0.5
Table 2 UCP-2 and -3 mRNA expression for each of the studied groups. Data is expressed as a ratio: optical density (OD) UCP-2
or -3 to OD of HPRT
Mean age Weight change
UCP-2 expression
(arbitrary units)
UCP-3 expression
(arbitrary units)
Adenocarcinoma patients Sex (years) at sampling (kg) Value Mean+s.e.m. Value Mean+s.e.m.
Group 1 (with weight loss) M 718.0 2.34 0.68
M 75.0 1.02 0.93
M6 3 +4.8 717.0 2.61 1.77+0.35 3.4 2.2+0.47
M 2.5 1.1 2.67
M 711.5 0.9 2.31
M 715.5 2.67 3.2
Group 2 (without weight loss) M 0 2.75 1.6
M 0 0.95 0.48
M +0.5 1.1 2.01+0.32 0.18 0.47+0.23
M7 0 +2.3 0 2.68 0.1
M 70.5 2.42 0.3
F 0 2.14 0.15
Controls (no malignancy no weight loss) M 0 2.02 0.04
F 0 2.5 1.18
F 0 3.15 2.41+0.17 0.85 0.39+0.2
F 0.2+4.6 0 2.41 0.02
F 0 2.31 0.14
M +0.5 2.04 0.08
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ratios to HPRT mRNA; these data are expressed graphically in Figure
1. UCP-2 mRNA levels were similar among all three groups. Mean
UCP-3 levels, however, were over ﬁve times higher in the cancer
patients with weight loss group than in controls. In the cancer with-
out weight loss group, mean UCP-3 levels were similar to controls.
DISCUSSION
This is the ﬁrst demonstration of up-regulation of UCPs in human
cancer associated weight loss. We have shown that UCP-3 mRNA
levels are increased in muscle only when weight loss is associated
with cancer. UCP-2 mRNA levels in muscle seems unaffected by
cancer either with or without weight loss. This ﬁnding correlates
with that previously demonstrated in the MAC-16 model of cancer
cachexia (although in this model UCP-2 was also increased in
skeletal muscle compared with non tumour-bearing controls).
Our data suggests that UCP-3 in skeletal muscle might either
contribute to weight loss, or be up-regulated as a consequence of
metabolic changes brought about by tissue loss. It is well recog-
nized that energy expenditure is increased in cancer often despite
reduced energy intake, and that it seems directly related to body
cell mass (Simons et al, 1999). That this increase in energy expen-
diture is directly related to the tumour effect is evidenced by the
fact that removal of tumour ensures prompt restoration of normal
metabolism (Luketich et al, 1990). UCP-3, when overexpressed in
the skeletal muscle of transgenic mice results in a lean phenotype,
with increased energy expenditure compared to controls (Clapham
et al, 2000). Over expression of UCP-3 in the skeletal muscle of
human cancer patients might contribute to increase energy expen-
diture and thus to weight loss.
Of course the fact that a protein associated with an increase in
energy expenditure is over expressed in a situation where energy
conservation would seem more appropriate, appears at ﬁrst to be
counterintuitive. However one of the putative roles of UCP-3 in
vivo is the facilitation of lipid substrate utilization. Certainly lipid
infusions result in increased skeletal muscle UCP-3 levels both in
vivo and in vitro (Hwang and Lane, 1999; Samec et al, 1999). Lipid
dysregulation occurs in cancer associated weight loss, with increases
in lipolysis (caused by cytokines and tumour derived lipolytic
factors) off-set by increases in lipid utilization so that plasma free
fatty acid levels may remain normal or only slightly elevated
(Younes et al, 1990). The role of UCP-3 may be to assist in the
utilization of excess FFA as fuel in the muscle or to prevent possi-
ble harmful effects of the intermediates of FFA metabolism.
Unfortunately in this study we were unable to obtain fasting FFA
levels in enough of the subjects studied to enable a statistically
meaningful correlation with UCP-3 levels. In our animal model,
however UCP-3 mRNA levels correlated well with plasma FFA
levels and there is no evidence to suggest that this would not be
the case in humans.
If the up-regulation of UCP-3 in skeletal muscle in human
cancers does result in increased energy expenditure and result in
weight loss, this offers potential new targets for therapeutic inter-
vention. Indeed, this observation may not be conﬁned to weight
loss associated with malignancy, but may also occur in other wast-
ing conditions such as, HIV disease, rheumatoid and cardiac
failure. Unfortunately due to the difﬁculty in obtaining laparotomy
specimens from these groups we were unable to address this speci-
ﬁc issue in the current study, but aim to investigate it at a future
date. If mechanisms could be found to block the up-regulation of
UCP-3 in malignancy and this resulted in a reduction in metabolic
rate, weight stabilization may occur. Cachexia is one of the most
important contributors to mortality in cancer, and its arrest is
likely to lead to meaningful increases in survival time.
ACKNOWLEDGEMENTS
The authors would like to thank Dr Robin Walker, Gastroenterol-
ogy Unit, University Hospital Aintree, who provided ﬁnancial
support for Dr Collins.
REFERENCES
Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G (2000) Increased
gene expression of brown fat uncoupling protein (UCP)1 and skeletal
muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res
60: 2405–2410
Bosaeus I, Daneryd P, Svanberg E, Lundholm K (2001) Dietary intake and
resting energy expenditure in relation to weight loss in unselected cancer
patients. Int J Cancer 93: 380–383
Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A, Seydoux J,
Muzzin P, Giacobino JP (1997) Uncoupling protein-3: a new member of
the mitochondrial carrier family with tissue speciﬁc expression. FEBS Lett
408: 39–42
Clapham J, Arch JRS, Chapman H, Haynes A, Lister C, Moore GBT, Piercy V,
Carter SA, Lehner I, Smith SA, Beeley LJ, Godden RJ, Herrity N, Skehel M,
Changani K, Hockings PD, Reid DG, Squires SM, Hatcher J, Trail B, Latc-
ham J, Rastan S, Harper AJ, Cadenes S, Buckingham JA, Brand M, Abunin
A (2000) Mice overexpressing human uncoupling protein-3 in skeletal
muscle are hyperphagic and lean. Nature 406: 415–418
De Wyes WD, Begg D, Lavin PT, Band PR, Bennet JM, Bertino JR, Cohen
MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Jhonson GJ, Moer-
tel CG, Oaken MM, Perlia C, Rowenbaum C, Silverstein MN, Skeel RT,
Spnzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to
chemotherapy in cancer patients. Am J Med 69: 491–497
Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-meyrueis
C, Bouillard F, Seldin MF, Surwit RS, Ricquier D, Wardenm CH (1997)
Nature Genet 15: 269–272
Hwang C, Lane D (1999) Up-regulation of uncoupling protein-3 by fatty acid
in C2C12 myotubes. Biochem Biophys Res Commun 25: 464–469
Klaus S, Casteilla L, Bouillaud F, Ricquier D (1991) The uncoupling protein
UCP: a membranous mitochondrial ion carrier exclusively expressed in
brown adipose tissue. Int J Biochem 23: 791–801
Luketich JD, Mullen JL, Feurer ID, Sternlieb J, Fried RC (1990) Ablation of
abnormal energy expenditure by curative tumour resection. Arch Surg 125:
337–341
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
U
C
P
 
m
R
N
A
:
H
P
R
T
 
m
R
N
A
3
2.5
2
1.5
1
0.5
0
controls
cancer, no weight loss
cancer, weight loss P<0.02
UCP-2 UCP-3
Figure 1 Mean UCP-2 and UCP-3 levels for the studied groups. Data is
expressed as a ratio: optical density (OD) UCP-2 or -3 to OD of HPRT
+s.e.m.
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